The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients

Mayo Clinic

Status: Terminated

Conditions: Palliative Medicine

Treatments: Diagnostic Test: Pharmacogenomics testing; Other: Pharmacist review

Study type: Interventional

Funder types: Other

Identifiers

NCT04251520

18-010761

Details and patient eligibility

About

Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.

Full description

Participants in the study will be randomized to A) standard of care, B) standard of care with medication therapy management provided by a pharmacist, or C) standard of care with medication therapy management by a pharmacist who has access to the patient's pharmacogenomics profile accessible to guide them. We will be measuring level of symptom control in each group over the subsequent 6 months.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• English speaking
• Age 18 years and older
• Palliative Medicine is consulted for the first time in either the outpatient setting for symptom management and plan to continue to follow up with the Palliative Medicine team in the outpatient setting for the foreseeable future.
• Insurance accepted at Mayo Clinic Arizona.
• Live within metro Phoenix area.

Exclusion criteria

• Vulnerable adults
• Under 18 years of age
• Pregnant Patients
• Subjects whose medical insurance requires use of specific pharmacies
• Non English Speaking Patients
• Patients that lack capacity for medical decision making
• Patients who live outside the metro Phoenix area
• Patients who are lost to follow up secondary to enrolling in hospice, die or failure to show or answer surveys within 2 months of enrollment.
• Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
• Patient's previously established within the Palliative Medicine Clinic who receive ongoing Palliative Medicine services.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

2 participants in 3 patient groups

Control Group

No Intervention group

Description:

Standard care by Palliative Medicine physician

Intervention Group A

Experimental group

Description:

Standard care by Palliative medicine physician plus pharmacist review of medications

Treatment:

Other: Pharmacist review

Intervention Group B

Experimental group

Description:

Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review

Treatment:

Other: Pharmacist review

Diagnostic Test: Pharmacogenomics testing